Tirzepatide Cost 2026: Zepbound Price Without Insurance

Without insurance, the manufacturer self-pay route is LillyDirect, which sells both the Zepbound KwikPen and single-dose vials: $299 per month for the 2.5mg starting dose, $399 for 5mg, and $449 for 7.5mg and up, as long as you refill within 45 days of your last delivery; miss that window and higher doses revert to $499 (7.5mg) or $699 (10mg-15mg). Delivery is free, or you can pick up at Walmart Pharmacy, and you buy needles separately. Lilly lists Zepbound at $499 to $1,086.37 per fill, and a pharmacy cash price can differ. If you have commercial insurance that does not cover Zepbound, the savings card lets you pay as low as $499 for a 1-month single-dose pen fill. If those numbers do not fit your budget, telehealth programs that prescribe compounded semaglutide (not FDA-approved and not reviewed by the FDA for safety, effectiveness, or quality) start lower, for example $99 at Strut, $149.25 at SkinnyRx, $179 at TrimRx, and $179 for the first month at MEDVi. The SURMOUNT-5 head-to-head compared brand products, so its results do not describe compounded ones. Prices re-checked on September 11, 2026; confirm current pricing at checkout, since manufacturer self-pay programs change without notice.

Coverage varies by plan. Where covered, expect prior authorization that may require BMI of 30 or higher (or 27 with a weight-related condition), and sometimes step therapy or documented lifestyle program participation. With active coverage for the single-dose pen, the Lilly savings card can bring your cost as low as $25 per month. On Medicare Part D, Lilly says the Medicare GLP-1 Bridge may cover the Zepbound KwikPen for weight management at no more than $50 per month starting July 1, 2026, if you have a BMI of 35 or higher, or 27 or higher with certain weight-related conditions. If your prescription is for diagnosed moderate-to-severe obstructive sleep apnea, your Part D plan may cover it instead. State Medicaid coverage varies. Call the number on your insurance card and ask specifically about Zepbound with your diagnosis before assuming either answer.

Nothing chemically. Zepbound and Mounjaro are the same molecule, tirzepatide, made by the same manufacturer at the same doses. The difference is the FDA label: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management and moderate-to-severe obstructive sleep apnea with obesity. The label difference drives coverage more than list price: Lilly lists Mounjaro at $1,112.16 per fill and Zepbound at up to $1,086.37. If you have type 2 diabetes, ask your plan about Mounjaro, and Lilly offers a Mounjaro Savings Card if you have commercial insurance. If you are prescribed tirzepatide for weight alone, you are in Zepbound territory where coverage is the exception and self-pay channels matter. This is also why prescribing Mounjaro off-label for weight to capture diabetes coverage does not work: plans verify the diagnosis during prior authorization. Choose the product that matches your actual diagnosis and then optimize the channel, because the medication in the pen or vial is identical.

The SURMOUNT-1 trial published in the New England Journal of Medicine in 2022 recorded 20.9% average body weight loss at 72 weeks on the 15mg dose, with 91% of participants losing at least 5% of body weight. In cost terms, Lilly defines a month of Zepbound as 28 days, so 72 weeks is 18 fills; at the $449 on-time refill price for 7.5mg and up, 18 fills come to $8,082, and at the $699 lapsed price for 10mg-15mg they come to $12,582. SURMOUNT-5 measured 13.7% for brand semaglutide, and no trial here studied compounded semaglutide, so a cost per pound for a compounded program cannot be derived from these results. Individual results spread widely around averages, and in the SURMOUNT-4 trial (JAMA, 2024), participants switched to placebo regained much of the weight they had lost, so budget as if you and your provider may continue treatment rather than for a one-time course.

LillyDirect sells the single-dose vial and the multi-dose KwikPen at the same self-pay prices: $299-$449 per month with an on-time refill, up to $699 if you miss the 45-day refill window on higher doses. The single-dose pen goes through insurance instead: with coverage you may pay as low as $25, and with commercial insurance that does not cover it the savings card brings a 1-month fill as low as $499, against a list price of up to $1,086.37 per fill. The practical difference for you is administration: vials require drawing your dose with a new needle and syringe each week, the KwikPen holds all four weekly doses and needs a new pen needle for each injection, and each single-dose pen includes its needle. The medication inside is the same FDA-approved tirzepatide.

Compounded tirzepatide and compounded semaglutide are both sold through telehealth programs, including some we list: HealthRx lists compounded tirzepatide from $179 per month on its 12-month plan, and Sprout from $199. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality, and the SURMOUNT and STEP trial results come from brand products, not compounded ones. LillyDirect KwikPen and vials at $299-$449 (on-time refill) are the way to stay on brand tirzepatide at a self-pay price. The FDA advises getting your prescription from your doctor and filling it at a state-licensed pharmacy.

Channel determines the annual number more than anything else. Lilly defines a month of Zepbound as 28 days, so a year is 13 fills. Covered commercial insurance with the savings card: as low as $325 per year at $25 per fill, plus visit copays. Medicare GLP-1 Bridge: no more than $650 per year at $50 per fill, if you qualify under the terms Lilly lists. LillyDirect self-pay KwikPen or vials: $3,887 at $299 per fill to $5,837 at $449 per fill if you refill on time; missing the 45-day refill window on 10mg-15mg pushes that toward $9,087 at $699. Two budgeting realities: dose escalation is standard protocol, so model your year on a maintenance dose rather than the starting tier, and the SURMOUNT-4 trial reported weight regain in participants switched to placebo, so budget for the possibility of multi-year treatment if you and your provider continue it, not only a single 12-month course.

Through LillyDirect KwikPen or vials, yes: the 2.5mg starting dose runs $299 per month, 5mg runs $399, and 7.5mg and up runs $449, provided you refill within 45 days of your last delivery; miss that window and 7.5mg reverts to $499 while 10mg-15mg reverts to $699. Lilly notes that 2.5mg is a starting dose and is not approved as a maintenance dose, so the $299 figure understates your steady-state cost. The savings card price with insurance coverage does not scale with dose, which flips the math: if you self-pay, the maintenance dose you and your prescriber settle on drives your cost (and so does refilling on time). In SURMOUNT-1, the 5mg group averaged 15% weight loss at 72 weeks versus 20.9% at 15mg (individual results vary), so which dose fits your results and side effects is a conversation for your prescriber, and it has a price: 5mg at $399 instead of $449 saves you $50 per fill, or $650 over 13 fills a year, and more if a missed refill would have pushed you to $699.

Work the sequence: first call the member number on your card and ask whether Zepbound is on formulary, what tier, and what the prior authorization requires. Typical criteria: BMI of 30 or higher, or 27 with a documented weight-related condition like hypertension or type 2 diabetes, sometimes plus documented participation in a lifestyle program. Second, have your prescriber submit the prior authorization with complete documentation the first time. Third, if you have diagnosed moderate-to-severe obstructive sleep apnea, ask your prescriber about Zepbound under its OSA indication; if you have Medicare Part D, your plan may cover that use. For weight management on Part D, ask about the Medicare GLP-1 Bridge, which Lilly says may cover the Zepbound KwikPen at no more than $50 per month starting July 1, 2026. Fourth, appeal denials when the clinical criteria are actually met. Fifth, check every open enrollment whether your employer added GLP-1 coverage, because it shifts year to year.

Only if you have type 2 diabetes and your plan covers Mounjaro. Mounjaro and Zepbound are the identical tirzepatide molecule, but insurance treats the labels differently: weight-prescribed Zepbound faces exclusions and prior authorization walls, and Lilly offers a Mounjaro Savings Card if you have commercial insurance. Without a diabetes diagnosis, the path inverts. You cannot legitimately access diabetes-label coverage, plans verify the diagnosis during authorization, and Lilly list prices for the two products are close ($1,112.16 per fill for Mounjaro, up to $1,086.37 for Zepbound), so Zepbound through the LillyDirect KwikPen or vials at $299-$449 (on-time refill; up to $699 if it lapses) becomes the cheaper legitimate route. If you have prediabetes, an honest conversation with your prescriber about your actual diagnosis matters, because Mounjaro is approved for type 2 diabetes, not prediabetes. Match the product to your real diagnosis, then optimize the channel within that lane; label-shopping without the diagnosis fails at prior authorization and wastes weeks.